Association of serum YKL-40 levels with the presence and severity of coronary artery disease in patients with obstructive sleep apnea syndrome Abstract Purpose: Current evidence supports a robust association between obstructive sleep apnea syndrome (OSAS) and the risk of coronary artery disease (CAD). YKL-40, a 40 kDa heparin-and chitin-binding glycoprotein, is found to be associated with the presence of CAD. is study aims to examine the association of serum levels of YKL-40 with the presence and severity of CAD in patients with OSAS.
Obstructive sleep apnea syndrome (OSAS) is characterized by recurrent episodes of complete or partial obstruction of the upper airway during sleep, accompanied by an oxygen desaturation and terminated by brief arousals which result in marked sleep fragmentation [1] . OSAS has a relatively high prevalence in the developed world: 4% in men and 2% in women [2] . OSAS has been reported to signi cantly increase the risk of cardiovascular disease, including hypertension, heart failure, arrhythmia, coronary artery disease (CAD) and stroke [3] . OSAS patients have a high morbidity and mortality due to cardiovascular disease, particularly CAD.
YKL-40, also named cartilage glycoprotein-39 or chitinase-3-like-1, is a heparin-and chitin-binding glycoprotein and a member of the mammalian chitinase-like protein family [4] . A variety of human cell types, including activated macrophages, neutrophils, chondrocytes, vascular smooth muscle cells and cancer cells, are found to produce and secrete YKL-40 [5] . YKL-40 is considered an in ammatory marker associated with both acute and chronic in ammation and with an established role in extracellular remodeling and angiogenesis [6] . In ammation is implicated in the pathogenesis of both OSAS and CAD [7] . In addition, YKL-40 is closely related to both the early and late phases of the atherosclerotic process [8] . Recent studies have demonstrated elevated levels of serum YKL-40 in CAD patients [9] ; therefore, it has been hypothesized that serum YKL-40 levels may be associated with the development of CAD in OSAS patients.
Previous studies have reported on serum YKL-40 levels in CAD patients; however, no study on the association of serum YKL-40 levels with the presence and severity of CAD in OSAS patients has been performed. In this study, serum levels of YKL-40 in OSAS patients, with and without CAD, were examined in order to assess its role in the pathophysiology of CAD in OSAS patients.
Materials and Methods

Study population
A consecutive population of 246 subjects with clinical symptoms of sleep apnea, which was examined by polysomnography (PSG) from August 2010 to October 2012 in General Hospital of People's Liberation Army, was enrolled in this study. OSAS was established according to clinical and polysomnographic criteria. Apnea-hypopnea index (AHI) was de ned as the frequency of apnea and hypopnea per hour. Subjects with AHI ≥5 were considered to have OSAS. Patients were excluded if they had a history of arterial hypertension, chronic obstructive pulmonary diseases (COPD) or other pulmonary disorders, infectious upper airway disorders, diabetes mellitus, and malignancy. e study protocol was approved by the Research Ethics Committee of the General Hospital of People's Liberation Army, and all patients gave their informed consent before commencement of the study.
Coronary angiography
CAD was de ned as subjects who had angiographic evidence of stenosis 50% in at least one major coronary artery. OSAS patients were then divided into two groups, with or without CAD, 134 and 112 patients, respectively, based on visual angiographic results. e severity of CAD was assessed by assigning scores to each of the 15 segments. e coronary atherosclerosis index (CAI) was de ned as the sum of these scores: grade 0 was de ned as no signi cant stenosis; grade 1 was de ned as stenosis of less than 25%; grade 2 was de ned as 25 to 49% stenosis; grade 3 was de ne as 50 to 74% stenosis; and, grade 4 was more than 75% stenosis. us, the highest possible score was 60 [10] . CAI was graded by two evaluators who were blinded to the results.
Laboratory examinations
Venous blood was collected a er a minimum of 10 hours of overnight fasting. Serum samples were stored at -80°C until assessment was carried out. Serum YKL-40 levels were determined by a commercially available enzyme immunoassay kit ( uidel, San Diego, CA, USA) according to the manufacturer's instructions. Body Mass Index (BMI) was calculated as weight in kilograms divided by height squared in meters (kg m-2).
Statistical analysis
Statistical analysis was carried out using SPSS version 13.0 so ware program (SPSS Inc, Chicago, Illinois, USA). Data are displayed as means±SD or median (interquartile range). e Kolmogorov-Smirnov test was used to analyze the data normality. Unpaired t-test or Mann-Whitney U test were utilized to compare the characteristics between OSAS patients with and without CAD. Univariate analysis was performed and the variables with a P<0.20 were then entered into a backward stepwise multivariate logistic regression model to calculate the odds ratio values (OR) and 95% con dence intervals (CI) for the presence of CAD in OSAS patients. Spearman correlation analysis was performed to evaluate the correlation between serum YKL-40 levels and CAI. Di erences were considered signi cant at P<0.05.
Results
Baseline clinical characteristics
Increased levels of LDL-C were found in OSAS patients with CAD compared with those without CAD. No signi cant differences were observed in other characteristics between the two groups. e clinical characteristics of the two groups are presented in Table 1 .
Serum YKL-40 levels in relation to CAD
OSAS patients with CAD had signi cantly elevated levels of serum YKL-40 compared with those without CAD ( Discussion is study provides the rst report of the association of serum YKL-40 levels with the presence and severity of CAD in patients with OSAS. ese results indicate that serum levels of YKL-40 were signi cantly elevated in OSAS patients with CAD compared with those without CAD. Increased serum levels of YKL-40 were signi cantly associated with the development of CAD in patients with OSAS. In addition, Spearman correlation analysis showed that serum YKL-40 levels were correlated with CAI.
Recent evidence revealed that OSAS patients showed a signi cantly increased risk of developing cardiovascular disease, in particularly CAD. In 40-70 year-old males, subjects with severe OSAS (AHI≥30 events/hour) were nearly 70% more likely to develop CAD compared with those without OSAS [11] . Sleep Heart Health Study (SHHS) provide epidemiologic evidence for a causal role of OSAS in the incidence of CAD and CAD-related mortality, which indicated the risk of CAD-related death in the male subset of this cohort tracked with all-cause mortality and was 70% greater in those with AHI≥15 events/hour compared with una ected individuals over an eight year follow-up of more than 6000 individuals [12] . Another study reported an increased risk of CAD with increasing AHI, even when adjusted for hypertension and BMI [13] . ese studies provide supportive evidence that OSAS is a risk factor for incident CAD and for CAD-related mortality; therefore, it is essential that the risk of developing CAD in OSAS patients be evaluated and that strategies to prevent CAD for patients with OSAS be developed.
Biomarkers in serum are now considered an important method for predicting the presence and progression of di erent diseases. YKL-40, a new in ammatory marker, promotes chemotaxis, cell attachment and migration of vascular smooth muscle cells and the formation of branching tubules, indicating that YKL-40 plays a role in angiogenesis [14] . Kucur et al. reported that serum YKL-40 levels were signi cantly elevated in CAD patients compared with healthy controls [9] . In addition, serum YKL-40 concentration is found to be an independent predictor of 10 year all-cause and cardiovascular mortality in subjects with type 2 diabetes [15] . is study was undertaken in order to test the hypothesis that there are signi cant di erences in the levels of serum YKL-40 between OSAS patients with CAD and those without CAD. Our results indicated that the levels of serum YKL-40 were signi cantly elevated in OSAS patients with CAD compared with those without CAD. ese data provide important evidence to support the addition of serum YKL-40 to the list of traditional risk factors for the assessment of cardiovascular risk in the primary prevention of CAD. e current study also revealed that serum levels of YKL-40 were associated with the severity of CAD which is assessed using CAI in patients with OSAS. Similar results were found in another study that found that increased serum YKL-40 levels were associated with angiographic lesion progression in patients with CAD [16] . In contrast, a study performed in patients with stable ischemic heart disease suggested that levels of serum YKL-40 did not correlate with the degree of CAD, assessed using di erent scoring systems [17] . e explanation for these con icting data is unclear but may be attributable to di erences in disease advancement, populations or assays applied, or incomplete control for confounding variables. YKL-40 may play a role in the development and progression of CAD in OSAS patients. Serum YKL-40 could be employed as an independent risk predictor for the presence and severity of CAD in OSAS patients. Further investigations will be needed to explain the exact role of YKL-40 in the presence or progression of CAD in OSAS patients. Our studies also found that patients with statin treatment showed lower levels of serum YKL-40, indicating that statin could reduce serum YKL-40 levels. is is consistent with a study by Mygind et al. that reported that serum YKL-40 was signi cantly higher in non-statin-treated CAD patients compared with statin-treated ones [18] . YKL-40 was found in several studies to be associated with prognosis in patients with stable CAD [19] [20] [21] . us, YKL-40 may be utilized as a biomarker to predict the prognosis of CAD patients.
is study has several potential limitations. First, the sample size was not large enough to reach de nitive conclusions and further studies with great numbers are warranted. Secondly, our study is of cross-sectional design, and the causative relation must be con rmed by future longitudinal studies. Last, the di erences in serum YKL-40 levels between OSAS patients and healthy controls were not assessed. Serum YKL-40 levels were elevated in obese subjects [22] and patients with in ammation-related with disease, such as diabetes [23] and rheumatoid arthritis [24] , compared with healthy controls. OSAS is associated with obesity and in ammation [7] ; therefore, serum YKL-40 is hypothesized to be elevated in OSAS patients without CAD compared with healthy controls. Further studies are needed to determine this hypothesis.
In conclusion, OSAS patients with CAD had signi cantly elevated serum levels of YKL-40 compared with those without CAD. Serum levels of YKL-40 were positively correlated with the severity of CAD. Serum levels of YKL-40 may serve as a new biomarker and may be useful, in addition to traditional diagnostic methods, for assessing the presence and severity of CAD in OSAS patients.
